Dose Uniformity & Emitted Dose Testing

Aerosol Science

Compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation document emitted dose, dose uniformity, and sources of variability for each study.

Purpose & when to use

Dose Uniformity and Emitted Dose (DU / ED) testing measures how much active or tracer reaches a defined collection point per actuation, and how consistent that delivery stays shot-to-shot and device-to-device. Compendial collection trains, controlled flow and actuation, and HPLC / ELISA / qPCR-ddPCR quantitation deliver per-shot dose and variability metrics aligned to USP <601>, USP <1601>, and FDA MDI / DPI / nasal-spray guidances. DU / ED is foundational for:

Per-actuation emitted dose and dose-uniformity packages for MDIs, DPIs, nebulizers, and nasal sprays — submission-grade datasets aligned to USP <601>, USP <1601>, and FDA MDI / DPI / nasal guidances.
In vitro bioequivalence and comparability packages for predicate and lifecycle changes — dose-uniformity trending and statistical equivalence framing under FDA bioequivalence and ICH Q5E guidance.
Formulation and component-tolerance screening during development — fast shot-to-shot dose checks for valve, pump, nozzle, or excipient changes under FDA development-stage CMC guidance.
Drift investigation across fill level, aging, storage conditions, and device wear — supports stability and shelf-life packages under USP <601> and ICH Q1A framing.
Variability root-cause investigation when emitted dose exceeds spec — pairs with PSD and high-speed imaging under ICH Q9 quality-risk framing to isolate actuation, leakage, or component contributors.

Use DU / ED testing when emitted dose or dose uniformity is central to a regulatory or commercial decision, including submission packages, predicate comparisons, stability programs, and formulation development. The resulting data tie quantitation to a controlled actuation, flow, and collection setup documented to support inspection.

Built for inhalation, intranasal, and oral drug delivery

DU / ED testing spans the device classes where per-actuation dose is the central performance attribute — pharmaceutical inhalation and intranasal devices plus oral spray products under a documented quality system.

MDIMetered-dose inhalers
DPIDry-powder inhalers
NebulizerLiquid aerosol generators
Nasal sprayIntranasal delivery
Oral spraySublingual and topical-oral

Instrumentation & measurement ranges

We select the platform based on the device class, active, and regulatory framework. Each component is defined during study planning and documented in the final report.

1 – 100 L/mininduction-port-flow

Compendial collection trains (USP-aligned fixtures)

USP-aligned induction port, mouthpiece adapters, and nasal / oral interfaces — compliant geometry for emitted-dose collection across MDI, DPI, nebulizer, and nasal-spray devices.

1 – 100 L/mincontrolled-flow

Mass-flow controllers and inhalation profile rigs

Calibrated flow control for steady-state and breathing-simulation profiles — pinned by mass-flow controllers and logged shot-by-shot for traceable per-actuation conditions.

0.1 – 100 Nactuation-force

Stepper-driven actuation fixtures

Controlled stroke, force, and timing under stepper control — manual, pneumatic, or mechanical fixtures sized to mimic patient or operator use across the actuation envelope.

0.1 – 1000 µgper-actuation

Analytical quantitation suite (HPLC, ELISA, qPCR / ddPCR)

HPLC for small-molecule actives, ELISA for protein analytes, and qPCR / ddPCR for nucleic-acid actives — assay matched to the active and matrix on a per-study basis.

Test method options

Method	Strengths	Tradeoff	Aligned with
Compendial-aligned emitted dose and uniformity (USP <601> / <1601>)	Submission-grade per-actuation dose and uniformity datasets — the canonical compendial package under USP <601> and USP <1601>. Documented acceptance logic and statistical framing for FDA MDI / DPI / nasal submissions and lifecycle change packages.	Strict fixture, flow, and assay control overhead — best when the device is locked and the data is filing-bound.	USP <601>USP <1601>FDA MDI / DPI / nasal
Development screening for dose consistency	Faster iteration with reduced replicates — supports formulation, valve, pump, and component-tolerance screening under FDA development-stage CMC framing. Same fixtures as the compendial method but acceptance bands tuned for iteration speed over filing rigor — design-team-friendly cadence.	May require follow-on confirmation under compendial conditions before filing — bridge to the regulator-aligned method when the program approaches submission.	FDA MDI / DPI / nasal
Robustness study (actuation profile, flow, environment)	Surfaces sensitivity to actuation force, flow profile, fill level, and temperature — defines the use-condition envelope where dose stays in spec. Output feeds change-control packages and predicate comparisons under USP <601> and FDA MDI / DPI / nasal change-control framing.	More conditions per study increase sample count and analyst time — scope tightly to the variables that drive the decision.	USP <601>FDA MDI / DPI / nasal
Troubleshooting and root-cause investigation	Pinpoints sources of variability — valve, pump, viscosity, leakage, or actuator wear — using paired methods and instrument records. Often paired with PSD or plume geometry under ICH Q9 quality-risk framing so the investigation closes with a defensible CAPA package.	Iterative by nature — schedule unpredictability is higher than fixed-protocol studies; budget for two or three investigation rounds.	ICH Q9

Setup configurations

Each DU / ED study uses a configuration matched to the device, active, and regulatory framework. The setup combines compendial rigor, including controlled flow, actuation, and traceable collection, with the practical operating characteristics of the device under test. During study planning, we define the following test parameters:

Device interfaces

Mouthpiece adapters, induction ports, nasal and oral interfaces — geometry matched to the device class and the compendial frame under test.

Flow & actuation profiles

Mass-flow-controlled flow profiles, stepper-driven actuation force and stroke, and defined shot schedules — every parameter logged shot-by-shot.

Sample numbers

Replicates per device and across devices — power sized to declared shot-to-shot and device-to-device variability with documented statistical framing.

Media & handling

Collection-media selection, extraction-solvent compatibility, and documented storage for collected fractions and analytical samples.

Calibration & verification

Mass-flow controllers, actuation force, and assay calibration verified against traceable standards before each campaign and between condition blocks.

Methods anchored to the standards that matter

Each DU / ED study operates within a documented quality system aligned with regulatory frameworks for inhalation, intranasal, and oral-spray products. The four anchors below define the data requirements carried through to the Section 7 outputs.

ISO 17025AccreditedTesting-laboratory competence — documented methods, calibration traceability, and uncertainty contributors.
USP <601>AccreditedAerosols, nasal sprays, MDIs, and DPIs — performance quality tests including delivered-dose uniformity.
USP <1601>AlignedProducts for nebulization — characterization tests including aerosol output and dose.
FDA MDI / DPI / nasalAlignedChemistry, manufacturing, and controls plus bioequivalence framing for inhalation and intranasal submissions.

Key data outputs & reporting

Each DU / ED study documents the dose collected per actuation, uniformity statistics, and the underlying datasets. Standard outputs include emitted dose per shot, summary statistics such as mean, SD, and CV, dose-vs-shot trends where applicable, and traceable QA / QC controls. Results are formatted for submission packages, change-control documentation, or development decisions. Comparability programs, predicate studies, and stability time courses include additional deliverables beyond the standard report.

Primary outputs

Emitted dose per actuation and summary statistics across shots, devices, and lots (mean, SD, CV, condition deltas).
Dose-uniformity trending across shot number, fill level, or canister-life position with predefined acceptance bands.
Assay calibration, recovery, and uncertainty contributors documented alongside results for inspection-readiness.

Deliverables

#	Format	Contents
01	PDF report	Methods, controls, statistical framing, and acceptance logic.
02	CSV / XLSX datasets	Per-shot dose, replicate statistics, and condition deltas.
03	Figures	Dose-vs-shot plots, condition overlays, and distribution charts for internal review and submission appendices.

Extended deliverables · multi-arm comparability · stability · predicate studies

Comparability appendix — Side-by-side dose-vs-shot overlays plus statistical equivalence tests per ICH Q1E or product-specific predicate framing.
Stability time-course pack — Emitted-dose and uniformity trends across timepoints with predefined OOT criteria flagged per ICH Q1A.
Method-development notes — Fixture, actuation, and assay-selection rationale plus uncertainty contributors — for submission cover letters and inspection readiness.

QA / QC & data integrity

Each DU / ED study includes a documented QA / QC framework sized to the method plan. Controls and verification checks are selected for the regulatory framework, analytical method, and decision the data will support. These checks run alongside dose collection, are audited under our ISO 17025 quality system, and remain traceable from sample receipt through the final result. Recovery, system suitability, and matrix-effect checks are added when required by the assay.

Blanks and background controls for collection media plus fixture-residue checks before each campaign.

Replicate measurements and repeat runs to quantify shot-to-shot and device-to-device precision.

Assay controls — calibration standards, system suitability per assay, and spike-recovery on matrix-challenging analytes.

Flow and actuation verification logs alongside captured doses with mass-flow controller calibration records.

Chain of custody from sample receipt through analysis and final reporting.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)

17025Accredited testing

900+Studies Performed

17+Years in operation

300+Clients supported

Common questions

These answers address common questions from inhalation, intranasal, and oral-spray teams planning a dose uniformity or emitted dose study, including assay selection, fixture choice, replicate plans, comparability framing, and deliverables. They are starting points rather than study protocols. Most DU / ED studies require at least one custom configuration choice based on the device, active, or regulatory framework.

Q.Is emitted dose the same as delivered dose?

A.Emitted dose is the material collected at the device outlet using a defined compendial fixture. Delivered dose may require additional anatomical models, breathing simulations, or in vivo work. We define the appropriate collection point during study planning.

Q.Can you quantify biologics or nucleic-acid actives?

A.Yes. We use ELISA for protein analytes and qPCR / ddPCR for nucleic-acid actives. Assay controls, system suitability, and recovery are documented with the results. The study uses the same compendial fixtures, with the assay selected and tuned for the active.

Q.How many actuations should be tested?

A.The appropriate count depends on device output, assay sensitivity, and the comparability target. Submission packages typically use n=10+ devices, with replicates collected across canister positions. Development screening may use a leaner design. We define shot counts during study setup.

Q.What drives dose variability most often?

A.Common contributors include actuation force and timing, component tolerances in the valve, pump, or nozzle, leakage, and formulation viscosity. We control flow and actuation, log each shot, and document assay recovery so differences remain interpretable.

Q.What do you deliver?

A.Deliverables include a PDF report documenting methods, controls, statistical framing, and acceptance logic; CSV / XLSX datasets containing per-shot dose and replicate statistics; and figures such as dose-vs-shot plots, condition overlays, and distributions for internal review and submission appendices.

Standards & guidance

ARE Labs conducts DU / ED studies in alignment with the regulatory and consensus standards that govern dose delivery for inhalation, intranasal, and oral-spray products. Methods within our third-party accreditation scope are documented as accredited, including ISO 17025 and USP <601>. When we follow a standard outside that formal accreditation scope, the method is described as aligned or conformant where applicable. The cards below identify the standards most often used for DU / ED data packages.

Inhalation & Drug Delivery - Accredited

Related services & devices

Service

Dose Uniformity and Emitted Dose Testing